LeonaBio, Inc. (LONA): Total Liabilities
$64.36M
As of 2025-12-31
$23.30M
As of 2026-06-30
+40.9%
3-year compound annual growth
+64.9%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $64.36M | +361.8% | 2026-03-31, Balance as of period end |
| 2024-12-31 | $13.94M | -53.6% | 2026-03-31, Balance as of period end |
| 2023-12-31 | $30.06M | +30.6% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $23.02M | +110.7% | 2024-02-22, Balance as of period end |
| 2021-12-31 | $10.92M | +106.9% | 2023-03-23, Balance as of period end |
| 2020-12-31 | $5.28M | +8.6% | 2022-03-28, Balance as of period end |
| 2019-12-31 | $4.86M | n/a | 2021-03-25, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| LeonaBio, Inc. (LONA) | 2025-12-31 | $64.36M | +361.8% |
| IRulya Therapeutics Inc. (IRLA) | 2025-12-31 | $129.24M | +53.2% |
| Aligos Therapeutics, Inc. (ALGS) | 2025-12-31 | $34.99M | -64.7% |
| Surrozen, Inc. (SRZN) | 2025-12-31 | $286.49M | +310.2% |
| Protalix BioTherapeutics, Inc. (PLX) | 2025-12-31 | $34.12M | +12.9% |
| Anavex Life Sciences Corp. (AVXL) | 2025-09-30 | $8.95M | -41.5% |
| Alpha Cognition Inc. (ACOG) | 2025-12-31 | $17.20M | +47.7% |
| Armata Pharmaceuticals, Inc. (ARMP) | 2025-12-31 | $295.48M | +119.8% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $69.24M | +91.2% |
Compare LONA, IRLA, ALGS, SRZN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗